• Gamze Guney Eskiler Department of Medical Biology, Uludag University, Bursa, Turkey
  • Gulsah Cecener Department of Medical Biology, Uludag University, Bursa, Turkey
  • Gokhan Dikmen Center Research Laboratory, Eskisehir Osmangazi University, Eskisehir, Turkey
  • Lutfi Genc Department of Pharmaceutical Technology, Anadolu University, Eskisehir, Turkey
  • Unal Egeli Department of Medical Biology, Uludag University, Bursa, Turkey



Breast cancer, Tamoxifen, Solid lipid nanoparticles, Drug resistance


To overcome the acquired Tamoxifen (Tam) resistance in Tam-resistant breast cancer cells without damaging normal cells, we have examined the therapeutic efficacy of Tam-loaded solid lipid nanoparticles (SLNs). Tam-loaded SLNs were produced by hot homogenization method. After characterization, in vitro cytotoxic and apoptotic activity of Tam-SLNs were evaluated in MCF7, MCF7-TamR (Tam-resistant breast cancer cells) and MCF10A cells. Tam-SLNs had an average size nearly 300 nm and a zeta potential of approximately-40 mV. In vitro cytotoxicity results showed that Tam-SLNs indicated the cytotoxic and apoptotic activity on MCF7 and MCF7-TamR cells. We found that MCF7-TamR cell viability was also suppressed significantly by Tam-SLNs and thus, Tam-SLNs could delay and overcome Tam-resistance (p<0.05). Furthermore, the Tam-SLNs did not induce apoptosis on MCF10A control cells. The lowest MCF10A cell viability was 83.0% whereas MCF7 and MCF7-TamR (R↔ and R↑) cells viability are reduced to 21.98%, 27.5% and 29.4% at 10 µM of Tam-SLNs, respectively (p<0.05). The obtained results were supported by apoptosis assays. SLNs-delivery system provided therapeutic efficacy to overcome Tam-resistance thanks to unique features of SLNs including small size, drug accumulation in the tumor site and controlled drug release. Therefore, Tam-SLNs may have therapeutic potential for the treatment of TAM-resistant breast cancer.


Download data is not yet available.


Gradishar WJ. Tamoxifen-what next? Oncologist 2004;9:378–84.

Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009;9:29–33.

García-Becerra R, Santos N, Díaz L, Camacho J. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 2012;14:108–45.

Nass N, Kalinski T. Tamoxifen resistance: from cell culture experiments towards novel biomarkers. Pathol Res Pract 2015;211:189–97.

Viedma-Rodrïguez R, Baiza-Gutman L, Salamanca‑Gomez F, Diaz‑Zaragoza M, Martïnez-Hernandez G, Ruiz Esparza‑Garrido R, et al. Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review). Oncol Rep 2014;32:3–15.

Sutradhar KB, Amin ML. Nanotechnology in cancer drug delivery and selective targeting. ISRN Nanotechnol 2014. [Article in Press]

Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Delivery Rev 2013;65:1866–79.

Lasoń E, Ogonowski J. Solid lipid nanoparticles–characteristics, application and obtaining. Chem Int 2011;65:960–7.

Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs-A review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004;113:151–70.

Bhaskar K, Anbu J, Ravichandiran V, Venkateswarlu V, Rao YM. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis 2009;8:6.

Güney G, Kutlu HM, Genç L. Preparation and characterization of ascorbic acid loaded solid lipid nanoparticles and investigation of their apoptotic effects. Colloids Surf B 2014;121:270–80.

Dikmen G, Guney G, Genc L. Characterization of solid lipid nanoparticles containing caffeic acid and determination of its effects on MCF-7 cells. Recent Pat Anticancer Drug Discovery 2015;10:224–32.

Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer–an overview and update. Mol Cell Endocrinol 2015;418:220–34.

Groenendijk FH, Bernards R. Drug resistance to targeted therapies: Déjà vu all over again. Mol Oncol 2014;8:1–17.

Hu CMJ, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 2012;83:1104–11.

Ravikumara NR, Madhusudhan B. Chitosan nanoparticles for tamoxifen delivery and cytotoxicity to MCF-7 and Vero cells. Pure Appl Chem 2011;83:2027–40.

Sant T, Moreira A, Antônio M, Oliveira M De, Nele M, Pinto JC. Effect of tamoxifen in RAFT mini-emulsion polymerization during the synthesis of polymer nanoparticles. Technical Sci Session 2014;24:25–30.

Lin YL, Chen CH, Wu HY, Tsai NM, Jian TY, Chang YC, et al. Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex. J Nanobiotechnol Biomed Central 2016;14:11.

Abbasalipourkabir R, Salehzadeh A, Abdullah R. Cytotoxicity of tamoxifen-loaded solid lipid nanoparticles. Delivery Nanoparticle 2009;59–70.

Ostad SN, Dehnad S, Nazari ZE, Fini ST, Mokhtari N, Shakibaie M, et al. Cytotoxic activities of silver nanoparticles and silver ions in parent and tamoxifen-resistant T47d human breast cancer cells and their combination effects with tamoxifen against resistant cells. Avicenna J Med Biotechnol 2010; 2:187–96.

Devalapally H, Duan Z, Seiden MV, Amiji MM. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res 2008;14:3193–203.



How to Cite

Eskiler, G. G., G. Cecener, G. Dikmen, L. Genc, and U. Egeli. “THE EFFECT OF SOLID LIPID NANOPARTICLES ON TAMOXIFEN-RESISTANT BREAST CANCER CELLS”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 8, no. 2, Sept. 2016, pp. 43-46, doi:10.22159/ijpps.2016v8s2.15220.



Original Article(s)